Senior Management Team
Marc Bazin, M.S. | President and Co-founder
Marc Bazin has worked in the pharmaceutical industry for over fifteen years. Expertise in organic synthesis, biomimetic catalysis and automation. Prior to founding HepatoChem in 2008, Marc Bazin was senior scientist at Pfizer in Cambridge, Massachusetts for 5 years. Prior to 2003 Marc Bazin worked at Pfizer in France for 5 years and was previously employed by Servier Research institute in 1995. Marc Bazin holds an MS in organic chemistry from the Conservatoire Nationnal des Arts et Métiers, Paris, France. Marc Bazin held a position of visiting scientist at Princeton University.
Jean-Marie Vallet, Ph.D., MBA | Director, Strategy Business Development
Dr. Vallet joined EnVivo, from Cyrma Consulting, LLC in June 2006. EnVivo Pharmaceuticals is a fully owned subsidiary of Boston-based Fidelity Investments. Dr. Vallet has over 20 years experience in a variety of research, marketing and business roles in life sciences, including in 14 years the pharmaceutical industry. Prior to founding Cyrma, a consulting company providing business development and strategic services to the biotech industry, Dr. Vallet most recently served as Vice President of Business and Commercial Development at Guilford Pharmaceuticals, Inc. Prior to Guilford, Dr. Vallet held senior level corporate development and marketing positions at Pierre Fabre (France), Parke-Davis (Germany), Warner Lambert (USA) and Bristol Myers Squibb (USA), completing numerous R&D, commercialization and M&A agreements with global pharmaceutical and life sciences companies in Europe and the US.
Marie Landel | Chief Financial Officer (President, Marie Landel & Associates)
Marie is a French CPA (Expert Comptable) and she holds an MBA from the European Business School (Paris, Frankfurt, London). She worked both as inside counsel for companies and as part of a CPA practice in France before starting her own practice in the US in 1989. She was the President of the French-American Chamber of Commerce for three years and is currently an active member of the New England trade advisor group to the French government.
Shelley Amster | Business Development Manager
Shelley Amster is Founder and Principal, ShelleyCO, LLC. Shelley is a connector and relationship catalyst. She nurtures healthy business and scientific relationships, uncovers new opportunities, and provides business development resources for her clients. With a large Rolodex of strong relationships from the healthcare and life science industries, Shelley has an extensive track record bringing leaders in industry, academia, government, the investment community, and (non) profit organizations together – locally, nationally, and globally.
Richard Gabriel, B.S., M.B.A.
Chief Operating Officer at GLG Pharma, LLC
CEO and President of Calix Corporation, parent company to Pharm-Eco Laboratories, Inc. Mr. Gabriel was instrumental in closing and managing over $135 million in contract revenue for Pharm-Eco Laboratories from milligrams to metric tons of cGMP pharmaceutical ingredients.
Successfully completed the formation of several joint ventures, limited liability companies and spin-offs that resulted in several public and private companies in the genetics, chemistry and pharmaceutical fields. From 2004 until 2008 he served as Chief Executive Officer and President for DNAPrint Genomics, Inc. He has been a part of the development of four successful drugs that include: Amprenavir (VX-478), Emtricitabine (FTC), Altretamine (Hexalen), Zalcitabine (DDC) and over 30 IND’s/ANDA’s and multiple Drug Master Files. Passed 3 FDA inspections with no 483 citations.
A Supervisory Board member of Biofrontera AG, a public German company focused on dermatology with several products nearing European approval.
John T. Groves, Ph.D. Professor of Chemistry, Princeton University | Co-founder.
John T. Groves is Hugh Stott Taylor Chair of Chemistry at Princeton University. He received his BS degree in chemistry at MIT and a PhD in organic chemistry with Ronald Breslow at Columbia University. He has worked in the fields of bioorganic, bioinorganic and biomimetic chemistry for 40 years, pioneering the study and application of oxometalloporphyrins in oxidative catalysis. He was elected to the American Academy of Arts and Sciences and received the Alfred Bader Award, the Cope Scholar Award and the Ira Remsen Award from the American Chemical Society. He has received the Frontiers in Biological Chemistry Award from the Max Planck Institute, the Grand Prix, Maison de la Chimie (Paris) and was elected Fellow of the Royal Society of Chemistry. In 2010 he received the Princeton University Keller Center Prize for Innovation for efforts leading to the development of HepatoChem.
Nick K. Terrett, Ph.D.
CSO of Ensemble Therapeutics
Nick is currently Chief Scientific Officer at Ensemble Therapeutics, a role he has held since May of 2006. In this role, Nick heads up drug discovery programs investigating the rapid synthesis of macrocycles and their application as drug candidates for disease relevant protein-protein interaction targets.
Nick has a PhD in chemistry from the University of Cambridge, and has extensive experience as a medicinal chemist for Glaxo and for Pfizer both in England and in the US. He worked initially in cardiovascular disease, and is an inventor on patents for the neutral endopeptidase inhibitor candoxatrilat. Later he led the chemistry team on cGMP phosphodiesterase inhibitors for angina and erectile dysfunction, and is an inventor on patents for Viagra® and Revatio®.
Nick established Pfizer’s combinatorial chemistry group and authored several related papers as well as one of the first textbooks in this field of chemistry. He also managed the Pfizer high throughput screening group and materials management, and played a key role in the global integration of the Pfizer, Warner-Lambert and Pharmacia compound collections. In 2003 Nick moved to the Pfizer Research Technology Center in Cambridge, Massachusetts, to lead the Chemical Sciences group investigating new targets for drug discovery and new chemistry technologies, before entering the biotech world with his move to Ensemble in 2006.